Introduction
============

The preanalytical phase (PP) is nowadays recognized as the most vulnerable part of the total testing process ([@b1-biochem-med-23-2-218-11]). The PP procedures involving phlebotomy are critical for obtaining diagnostic blood specimens: on the whole they represent a well known and recognized problem, probably among the most important issues in laboratory medicine ([@b2-biochem-med-23-2-218-11]--[@b5-biochem-med-23-2-218-11]). Lippi and Simundic recently advised to think outside the box and to address the extra-analytical processes that are more vulnerable to errors ([@b6-biochem-med-23-2-218-11]). With this aim, we demonstrate here that incorrect procedures during phlebotomy can be a source of spurious hyperkalaemia and hypocalcemia in patients' samples.

Case report
===========

A 45 years old male outpatient, with no apparent clinical complaints, wheelchair dependent, calls to our laboratory accredited by DICQ® (DICQ is a National System of Accreditation from Brazilian Society of Clinical Analyses based on ISO 15189 document), asking for a blood specimen collection at home, for performing a series of routine laboratory tests prescribed by his physician. The tests are the: total cholesterol (CHOL), HDL-cholesterol (HDL), triglycerides (TG), sodium (Na), potassium (K), total calcium (tCa), free calcium (fCa), urea, creatinine (CREA), total protein (TP), albumin (ALB), alkaline phosphatase (ALP) and routine blood count with platelets (CBC). The patient was asked to observe 12-hours overnight fasting and the blood collection was scheduled for 7 am, 3 work days after his call. Before blood collection, the median cubital vein was located on the left forearm using only a subcutaneous tissue transilluminator device (Venoscópio IV plus, Duan do Brasil, Sao Paulo, Brazil) --without tourniquet -- to prevent interference from venous stasis ([@b7-biochem-med-23-2-218-11]--[@b9-biochem-med-23-2-218-11]), and blood samples were collected using a 20-G straight needle (BD Vacuntainer ® Becton, Dickinson and Company Franklin Lakes, NJ, USA) connected to the holder, directly into the vacuum tubes (Greiner Bio-One GmbH, Kremsmünster, Austria). The order of different types of tube filling was: a) clot activator and gel separator tube, b) K~3~EDTA tube for CBC and c) a blood gas dedicated-syringe (Pico 50® with 80 I.U. lyophilized electrolyte-balanced lithium heparin, Radiometer Medical ApS, Denmark) without needle, which was directly connected to the needle-holder system in order to avoid double vein puncture. After collection, the tubes were properly mixed and transported from patient's house to the core laboratory by car at 20 ± 2 °C in upright position inside a transport box. The blood into syringe was transported at 4 ± 1 °C, as recommended by clinical laboratory standard institute C31-A2 document ([@b10-biochem-med-23-2-218-11]). The blood specimens (serum tube, cell blood count tube and dedicated syringe) arrived in core laboratory about one hour after blood collection and were immediately processed and analyzed (\< 15 min from the arrival time). The dedicated syringe was properly mixed and the free calcium was measured by ion-selective electrode on ABL 700® (Radiometer Medical ApS, Brønshøj, Denmark), according to the manufacturer's specifications and using proprietary reagents. Whole blood for CBC was gently mixed and analyzed on Sysmex® XE-2100D, Automated Hematology Analyzer (Sysmex Corporation®, Kobe, Japan). Serum vacuum tube was centrifuged at 1500 x g for 10min at room temperature. In sequence, the laboratory tests on serum were performed on the primary blood tube on Cobas® 6000 \< c501 \> module (Roche Diagnostics GmbH, Penzberg, Germany), according to the manufacturer's specifications and using proprietary reagents. All laboratory instruments had been previously calibrated against appropriate proprietary reference standard material and verified with the use of proprietary controls. Our evaluation of the within-run precision by internal quality control is shown as coefficients of variation (CVa). The results are shown in [table 1](#t1-biochem-med-23-2-218-11){ref-type="table"}. The laboratory staff (clinical chemistry specialist) contacted the patient by phone because some results (i.e. potassium, total calcium and free calcium) of the sample collected in dedicated syringe were out of the critical limits established by Kost ([@b11-biochem-med-23-2-218-11],[@b12-biochem-med-23-2-218-11]). The patient reported that he did not use topical medicines or intravenous solution in the last four months. A new blood collection (serum tube and dedicated syringe only) was scheduled for 12.30 pm of the same day. The venipuncture for the 2^nd^ blood collection was performed, by the same phlebotomist, in cephalic vein on the left forearm. The drawing order was: a) clot activator and gel separator tube, b) blood gas dedicated-syringe; both of the same brand and lot used for the first blood collection. So, during the 2^nd^ venipuncture the diagnostic blood specimen collection did not include a new EDTA vacuum tube. The following procedures were identical to the described above for the 1^st^ blood specimen collection. The 2^nd^ blood specimens arrived in core laboratory about 45 min after collection and were immediately processed and analyzed on the same analytical instruments. The results are shown in [table 1](#t1-biochem-med-23-2-218-11){ref-type="table"}.

Statistical analysis
====================

The reference change values (RCV) were determined to ascertain any clinically significant differences between the first and the second blood collection according to the formula RCV = 2^1/2^ × Z × \[(CVa)^2^ + (CV~w~)^2^\]^1/2^ where Z: z-score is 1.96 (5% standard normal deviation in bicaudal testing); CVa: analytical within run precision of the internal quality control and CVw: coefficient of variation within-subject ([@b13-biochem-med-23-2-218-11]) were applied. Mean % differences were determined according to the formula difference % mean = \[(1^st^ blood collection -- 2^nd^ blood collection)/1^st^ blood collection\] × 100.

Discussion
==========

In clinical laboratory the quality indicators are fundamental tools for quantifying the quality of a selected aspect of care by comparing it against a defined goal. For private laboratories the level of patient satisfaction with the diagnostic blood collection service is a very important quality indicator. With the aim to increase the patient satisfaction the procedure described above was implemented approximately six months ago in our laboratory, in order to avoid double venipuncture. This procedure is not explicitly stated in both international and national guidelines but is frequently performed in laboratories of South America countries. In order to avoid possible test result errors due to additive carryover, the correct order of blood drawing by venipuncture should be as follows: i) blood culture tube or tube without additive; ii) sodium citrate tube; iii) serum tube with or without clot activator and with or without gel separator; iv) heparin tube with or without gel separator and/or dedicated-syringe with heparin; v) EDTA tube with or without gel separator; and vi) glycolytic inhibitor tube. The Clinical Laboratory Standard Institute H03-A6 document ([@b14-biochem-med-23-2-218-11]) has standardized order of draw based on Calam and Cooper results ([@b15-biochem-med-23-2-218-11]). This document is widely used by laboratory quality managers to standardize the blood collection procedures ([@b16-biochem-med-23-2-218-11]). When our laboratory employees were retrained to eliminate this non conformity, regarding draw order, they reported that: "*During the maneuver to insert the syringe into the adapter of the tube holder, sometimes we risk to miss the vein: for this reason and thus to avoid repeating venipunctures, we would like to insert the syringe at the end of all tubes rather than at mid blood collection.*" Nonetheless, this patient's case demonstrates that something wrong can still arise from an apparently standardized procedure of tube order for blood drawing. At first sight, when looking at the potassium and calcium critical values from the 1^st^ collected patient's sample (dedicated-syringe), a main hypothesis of such a severe modification of blood potassium and calcium could be a chronic kidney disease. Obviously this supposition was discarded after checking Urea, CREA, TP and ALB results from the 1^st^ and 2^nd^ blood collections, thus the condition of the patient was judged far from critical. Until now two studies agreed in showing that the order of tube drawing did not affect routine biochemistry (e.g. potassium, magnesium, alkaline phosphatase, and iron), when closed system for blood collection from Sarstedt or BD were used ([@b17-biochem-med-23-2-218-11],[@b18-biochem-med-23-2-218-11]). Unfortunately these studies did not measure the calcium values in serum tubes collected after EDTA vacuum tubes and/or vacuum tubes produced by Greiner Bio-One. Moreover we previously found that different brands of *in vitro* diagnostic devices (e.g. vacuum tubes and syringes) have different performances in routine laboratory tests and that changes in the brands can increase laboratory variability ([@b19-biochem-med-23-2-218-11]--[@b23-biochem-med-23-2-218-11]). Future investigations should be planned to cover the impact of vacuum tubes brands on EDTA carryover. Several others articles showed spurious hyperkalaemia and hypocalcemia based on EDTA carryover ([@b24-biochem-med-23-2-218-11]--[@b26-biochem-med-23-2-218-11]). Cornes *et al*. after measuring EDTA in 117 hyperkalaemic samples showed that spurious hyperkalaemia due to kEDTA contamination was common (about 25% of all samples tested). In the 27 patients retested, serum potassium was within the reference range confirming the contamination with EDTA ([@b24-biochem-med-23-2-218-11]). In the present case we have estimated an EDTA carryover of 0.5 ∼ 0.6 mg/mL of blood into the dedicated syringe from the preceding EDTA-containing tube. It was predicted by stoichiometric calculation based on the observed reduction of Ca ions and on the molecular mass of EDTA. The estimation is based on the variation of the potassium concentration, from the K~3~EDTA tube to the syringe, taking into account that a mass concentration of 1.5 mg of K~3~EDTA per 1 mL of blood as an optimal anticoagulant level is declared ([@b27-biochem-med-23-2-218-11]). The K~3~EDTA carryover is the best hypothesis to justify the spurious results found in the dedicated syringe from the 1^st^ blood collection. Moreover when looking at total- and free-calcium results the decreased results observed in dedicated syringe appear not so proportionally reduced. Theoretically, the total amount of calcium in plasma is about 2.5 mmol/L and the normal amount of calcium in plasma that can be complexed by a sequestering agent is 1.15 mmol/L. The remaining calcium is bound to protein (e.g. albumin) and is scarcely available for sequestration by EDTA ([@b27-biochem-med-23-2-218-11]). In any case clinically significant differences were observed for potassium, total calcium and free calcium only in the blood of the dedicated syringe when mean percent differences were compared with RCV derived from biological variation ([Table 1](#t1-biochem-med-23-2-218-11){ref-type="table"}) ([@b28-biochem-med-23-2-218-11]). Obviously the quality specifications derived from biological variation are considered both very important and useful in the daily practice by the quality managers of the medical laboratories ([@b13-biochem-med-23-2-218-11],[@b29-biochem-med-23-2-218-11],[@b30-biochem-med-23-2-218-11]). Based on this depictive case we recommend the laboratory managers to train the phlebotomists as follows: 1) the dedicated needleless syringes for blood-gas must be connected to the needle-holder system immediately after serum tubes and before EDTA vacuum tubes; 2) to avoid double vein puncture the dedicated needleless syringes for free calcium determination must be connected to the needle-holder system immediately after serum tubes and before EDTA vacuum tubes.

In conclusion, we caution the laboratory managers about the current procedures advising to connect the syringes for blood gas and calcium tests at the end of all vacuum tubes; moreover we claim that the continuous training of the phlebotomists and of all the laboratory staff with regards to the effects of preanalytical interferences is a mandatory task in every modern clinical laboratory.

**Potential conflict of interest**

None declared.

###### 

Laboratory results.

  **Parameter**                   **Reference interval**   **Critical values (lower limit/upper limit)**   **1st blood collection**   **2nd blood collection**   **Mean % difference**   **RCV**   **CVa**   **CVw**                     
  ------------------------------- ------------------------ ----------------------------------------------- -------------------------- -------------------------- ----------------------- --------- --------- ------------- ------- ----- ------
  Total cholesterol (mmol/L)      4.22--7.12               NA                                              4.48                       \-                         4.50                    \-        −0.44     \-            15.69   1.7   5.4
  HDL-cholesterol (mmol/L)        0.78--1.66               NA                                              1.04                       \-                         1.03                    \-        0.96      \-            22.73   4.1   7.1
  Triglycerides (mmol/L)          0.64--3.16               NA                                              3.63                       \-                         3.60                    \-        0.83      \-            58.17   1.9   20.9
  Sodium (mmol/L)                 136--145                 120/160                                         138                        138                        139                     139       −0.72     −0.72         3.16    0.9   0.7
  Potassium (mmol/L)              3.5--5.1                 2.8/6.2                                         4.8                        **8.5**                    4.7                     4.5       2.08      **47.06**     13.86   1.4   4.8
  Total calcium (mmol/L)          2.15--2.55               1.50/3.25                                       2.36                       1.48                       2.37                    2.38      −0.42     −**60.81**    5.42    0.6   1.9
  Free calcium (mmol/L)           1.15--1.33               0.75/1.60                                       \-                         **0.15**                   \-                      1.21      \-        −**706.67**   5.00    0.6   1.7
  Urea (mmol/L)                   2.1--7.1                 NA/28.6                                         5.3                        \-                         5.2                     \-        1.89      \-            34.79   2.5   12.3
  Creatinine (μmol/L)             80--115                  NA/442                                          84                         \-                         85                      \-        −1.19     \-            17.91   2.4   6.0
  Total protein (g/L)             64--83                   NA                                              78                         \-                         77                      \-        1.28      \-            8.08    1.1   2.7
  Albumin (g/L)                   35--52                   NA                                              45                         \-                         46                      \-        −2.22     \-            9.12    1.1   3.1
  Alkaline phosphatase (μkat/L)   0.71--1.67               NA                                              1.28                       \-                         1.26                    \-        1.56      \-            19.04   2.5   6.4

Bold values are results outside of critical limits ([@b11-biochem-med-23-2-218-11],[@b12-biochem-med-23-2-218-11]) and bold mean % differences represent clinically significant variations, when compared with reference change value (RCV).

NA - not applied; CVa - analytical within run precision of the internal quality control, CVw - coefficient of variation within-subject ([@b13-biochem-med-23-2-218-11]).
